Recently, CanSinoBIO's subsidiary CanSinoBIO Co., Ltd. signed a cooperation development agreement with JENKEM's wholly-owned subsidiary Tianjin JENKEM Technology Co., Ltd. Both parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma, with the first patient administration expected to be completed within this year